Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting
The Journal of Allergy and Clinical Immunology: In Practice · 2025-01 · 13 (1) · 185-191.e3
DOI: 10.1016/j.jaip.2024.09.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025-01. Verfasst von Jenny Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif. Hauptthemen laut MEDLINE: Sesamum, Arachis, Desensitization, Immunologic, Allergens. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
BACKGROUND: Oral immunotherapy (OIT) for food allergy has been largely studied in older children within the context of clinical trials, and its availability has historically been limited for younger patients with food allergy. Data have shown that the most impact may actually be seen with the use of OIT in younger infants and toddlers. OBJECTIVE: To evaluate the safety and feasibility of OIT in subjects 24 months and younger in a real-world setting using commercially available food products. METHODS: This was a retrospective study of subjects 24 months and younger initiated on OIT for peanut, tree nut, or sesame allergy within the Scripps Clinic allergy department. Medical records were reviewed for data regarding initial oral food challenges, OIT, and adverse outcomes. RESULTS: Fifty-two subjects 24 months and younger were initiated on OIT. Most subjects (84.6%) were on single-food OIT, and some (15.4%) were on multifood OIT. No increased adverse outcomes were observed on multifood OIT. Of the 59 initial oral food challenges, objective reactions occurred during 42 challenges, most being low-grade reactions. During initial oral food challenges, 86.1% of peanut-allergic children tolerated 1/8 of 1 Bamba stick with no reaction. Most subjects (73.1%) updosed at home, and most (51.9%) had no reactions while updosing. Some had low-grade cutaneous reactions, none requiring epinephrine or emergency evaluation. CONCLUSIONS: OIT in infants is safe and feasible to perform in a real-world setting using commercially available food products with at-home updosing, thus increasing the availability of OIT for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
- Scripps Department of Research & Development, Scripps Health, San Diego, Calif.
- Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif. Electronic address: wangberg.hannah@scrippshealth.org.
Förderung
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Huang, J., Puglisi, L. H., Cook, K. A., Kelso, J. M., & Wangberg, H. (2025). Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting. The Journal of Allergy and Clinical Immunology: In Practice, 13(1), 185-191.e3. https://doi.org/10.1016/j.jaip.2024.09.025
Vancouver
Huang J, Puglisi LH, Cook KA, Kelso JM, Wangberg H. Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13(1):185-191.e3. doi:10.1016/j.jaip.2024.09.025
BibTeX
@article{Huang2025,
author = {Huang, Jenny and Puglisi, Leah H and Cook, Kevin A and Kelso, John M and Wangberg, Hannah},
title = {Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
volume = {13},
number = {1},
pages = {185--191.e3},
doi = {10.1016/j.jaip.2024.09.025}
}
EUVIMED